Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
The long noncoding RNA CARDINAL attenuates cardiac hypertrophy by modulating protein translation
Xin He, … , Da-Zhi Wang, Zhan-Peng Huang
Xin He, … , Da-Zhi Wang, Zhan-Peng Huang
Published May 14, 2024
Citation Information: J Clin Invest. 2024;134(13):e169112. https://doi.org/10.1172/JCI169112.
View: Text | PDF
Research Article Cardiology Development

The long noncoding RNA CARDINAL attenuates cardiac hypertrophy by modulating protein translation

  • Text
  • PDF
Abstract

One of the features of pathological cardiac hypertrophy is enhanced translation and protein synthesis. Translational inhibition has been shown to be an effective means of treating cardiac hypertrophy, although system-wide side effects are common. Regulators of translation, such as cardiac-specific long noncoding RNAs (lncRNAs), could provide new, more targeted therapeutic approaches to inhibit cardiac hypertrophy. Therefore, we generated mice lacking a previously identified lncRNA named CARDINAL to examine its cardiac function. We demonstrate that CARDINAL is a cardiac-specific, ribosome-associated lncRNA and show that its expression was induced in the heart upon pathological cardiac hypertrophy and that its deletion in mice exacerbated stress-induced cardiac hypertrophy and augmented protein translation. In contrast, overexpression of CARDINAL attenuated cardiac hypertrophy in vivo and in vitro and suppressed hypertrophy-induced protein translation. Mechanistically, CARDINAL interacted with developmentally regulated GTP-binding protein 1 (DRG1) and blocked its interaction with DRG family regulatory protein 1 (DFRP1); as a result, DRG1 was downregulated, thereby modulating the rate of protein translation in the heart in response to stress. This study provides evidence for the therapeutic potential of targeting cardiac-specific lncRNAs to suppress disease-induced translational changes and to treat cardiac hypertrophy and heart failure.

Authors

Xin He, Tiqun Yang, Yao Wei Lu, Gengze Wu, Gang Dai, Qing Ma, Mingming Zhang, Huimin Zhou, Tianxin Long, Youchen Yan, Zhuomin Liang, Chen Liu, William T. Pu, Yugang Dong, Jingsong Ou, Hong Chen, John D. Mably, Jiangui He, Da-Zhi Wang, Zhan-Peng Huang

×

Figure 5

CARDINAL overexpression attenuates cardiomyocyte hypertrophy.

Options: View larger image (or click on image) Download as PowerPoint

CARDINAL overexpression attenuates cardiomyocyte hypertrophy.
(A) Timel...
(A) Timeline for in vivo Cardinal gain-of-function analysis. (B) Relative expression of Cardinal (n ≥4 for each group) detected by RT-qPCR. (C) Ventricular weight/body weight ratio (n ≥4 for each group), (D) gross morphology (scale bars: 1 mm), (E) H&E staining (scale bars: 1 mm), (F) WGA staining (scale bars: 50 μm), (G) cardiomyocyte size quantification (n = 3 for each group), (H) Picrosirius red/Fast Green staining (scale bars: 1 mm), and (I) fibrosis area quantification (n ≥4 for each group) using cross sections, (J) relative expression of cardiac hypertrophy and fibrosis markers (n ≥4 for each group), and (K) percentage of fractional shortening (FS) of hearts from mice injected with AAV9-Ctrl or AAV9-Cardinal 4 weeks after sham or TAC surgery. (L) Immunofluorescence images (scale bars: 70 μm) and (M) cell area quantification of NRVCs infected with control virus or Ad-Cardinal treated using culture medium with or without PE (50 μM) for 48 hours. Violin plots were generated to show the median and 25th and 75th percentiles. At least 300 cells were measured for quantification in each group. (N) RT-qPCR results showing relative gene expression levels of hypertrophy markers in NRVCs infected with control virus or Ad-Cardinal treated in culture medium with or without PE (50 μM) for 24 hours (n = 3 for each group). *P < 0.05, **P < 0.01, and ***P < 0.001, by 2-tailed Student’s t test (I) or 2-way ANOVA with Tukey’s post hoc test (B, C, G, J, K, M, and N).

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts